J. Morgan

发表

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

J. Desai, G. Demetri, P. Larsen, 2006, Annals of Internal Medicine.

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

G. Demetri, S. George, J. Morgan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

G. Demetri, S. George, J. Morgan, 2015, Cancer.

Multimodality treatment of mesenteric desmoid tumours.

M. Bertagnolli, G. Demetri, C. Raut, 2008, European journal of cancer.

Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

Stephen A. Allsop, D. Neuberg, M. Mihm, 2015, Clinical Cancer Research.

Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate

J. Manola, M. Bertagnolli, G. Demetri, 2010, Annals of Surgical Oncology.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

A. D. Van den Abbeele, G. Demetri, J. Yap, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner

M. Ewen, D. Livingston, J. Decaprio, 1992, Cell.

Obligate Roles for p16Ink4a and p19Arf-p53 in the Suppression of Murine Pancreatic Neoplasia

M. Loda, R. DePinho, S. Signoretti, 2002, Molecular and Cellular Biology.

Imaging features of bone metastases in patients with gastrointestinal stromal tumors.

S. Silverman, G. Demetri, J. Glickman, 2012, Diagnostic and interventional radiology.

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

C. Paweletz, V. Velculescu, J. Fletcher, 2019, Clinical Cancer Research.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST

J. Blay, G. Demetri, A. Cesne, 2007 .

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

J. Ware, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

G. Demetri, H. Hurwitz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.

G. Demetri, F. Hodi, G. Shapiro, 2016 .

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

J. Manola, G. Demetri, M. Nucci, 2014, Cancer.

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

G. Demetri, R. Maki, G. Schwartz, 2008 .

Leiomyosarcoma of the Inferior Vena Cava: Survival After Aggressive Management

M. Bertagnolli, G. Demetri, C. Raut, 2007, Annals of Surgical Oncology.

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

J. Fletcher, G. Demetri, W. Tap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

J. Manola, G. Demetri, G. Shapiro, 2010, Clinical Cancer Research.

Primary intra‐abdominal melanoma arising in association with extracutaneous blue naevus: a report of two cases

A. Folpe, C. Raut, J. Morgan, 2020, Histopathology.

Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial

G. Demetri, S. George, J. Morgan, 2007 .

Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948).

R. Jain, Y. Boucher, G. Demetri, 2010 .

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

Sinem K. Saka, S. Gygi, M. Bertagnolli, 2022, British Journal of Cancer.

Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET

G. Demetri, J. Yap, R. Maki, 2008 .

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).

G. Jayson, J. Ware, J. Soria, 2011 .

7501 ORAL Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

J. Blay, G. Demetri, A. Cesne, 2007 .

Seven-year disease-free survival after radical pneumonectomy for a pulmonary artery sarcoma.

G. Couper, J. Morgan, P. Linden, 2013, The Journal of thoracic and cardiovascular surgery.

Cryopreservation of fetal skin is improved by extracellular trehalose.

M. Toner, J. Morgan, A. Eroğlu, 2002, Cryobiology.

Cutaneous angiosarcoma of the head and neck.

C. Raut, P. Devlin, E. Baldini, 2010 .

Epithelioid angiosarcoma of the uterus: a review of management

J. Morgan, R. Penson, A. Goodman, 2008, Archives of Gynecology and Obstetrics.

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Blay, G. Demetri, H. Borghaei, 2009, Clinical Cancer Research.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Xin Huang, J. Desai, G. Demetri, 2006, The Lancet.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Qian Wang, A. D. Van den Abbeele, Edwin Choy, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

J. Blay, G. Demetri, P. Stephenson, 2009, European journal of cancer.

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

M. Bertagnolli, J. Fletcher, G. Demetri, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.

G. Demetri, S. George, J. Morgan, 2019, European journal of cancer.

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009 .

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas

J. Desai, G. Demetri, D. Zahrieh, 2007, Cancer.

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

Jeffrey W. Clark, T. Lynch, P. Enzinger, 2004, Cancer.

Cancer Therapy: Clinical A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Blay, G. Demetri, H. Borghaei, 2009 .

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

G. Demetri, I. Ray-Coquard, P. Reichardt, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

G. Demetri, J. Baselga, D. Haber, 2014, BMC Cancer.

A phase I – II study of everolimus ( RAD 001 ) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

G. Demetri, I. Ray-Coquard, P. Reichardt, 2010 .

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

A. D. Van den Abbeele, C. Antonescu, J. Fletcher, 2009, Clinical Cancer Research.

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

David Zurakowski, Frederick J Schoen, Flavia Cassiola, 2007, The Lancet.

Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease

S. Ashley, C. Raut, J. Morgan, 2007, Current opinion in gastroenterology.

Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy

Ming-Hui Chen, J. Desai, G. Demetri, 2005 .

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

J. Desai, M. Bertagnolli, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

C. Antonescu, G. Demetri, A. Ligon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amulticenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST ) following failure of at least imatinib and sunitinib

G. Demetri, K. Ganjoo, S. George, 2013 .

Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors

A. D. Van den Abbeele, J. Manola, J. Desai, 2007, Clinical Cancer Research.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

J. Desai, G. Demetri, J. Verweij, 2006, The Lancet.

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

F. Hodi, F. Hodi, G. Shapiro, 2017, Cancer.

High rates of histopathologic discordance in sarcoma with implications for clinical care.

G. Demetri, C. Raut, E. Baldini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18.

D. Weisenburger, C. Reynolds, N. Harris, 1999, Cancer research.

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

Helen X. Chen, M. Burgess, G. Schwartz, 2021 .

Reply to W.F. Pirl et al

G. Demetri, S. Block, S. George, 2009 .

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

G. Demetri, S. George, J. Morgan, 2013, Clinical Cancer Research.

Small molecule tyrosine kinase inhibitor and depression.

G. Demetri, S. Block, S. George, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor

S. Kesari, J. Morgan, O. Baloglu, 2007, Journal of Neuro-Oncology.

Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)

A. Cesne, S. Schuetze, P. Casali, 2007 .

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

Jeffrey W. Clark, C. Earle, S. Grossman, 2002, Cancer.

Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)

J. Desai, J. Fletcher, G. Demetri, 2005 .

Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy.

G. Demetri, J. Baselga, D. Haber, 2013 .

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

G. Demetri, R. Maki, S. George, 2008, Journal of the National Cancer Institute.

Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

R. Jain, Y. Boucher, G. Demetri, 2012, PloS one.

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, M. Bertagnolli, G. Demetri, 2006, Journal of Clinical Oncology.

Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM).

A. D. Van den Abbeele, S. Silverman, K. Tuncali, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)

J. Blay, G. Demetri, I. Ray-Coquard, 2008 .

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

J. Manola, J. Desai, G. Demetri, 2005 .

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial

G. Demetri, S. George, C. Devine, 2008 .

Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.

P. Catalano, G. Demetri, S. George, 2020 .

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.

J. Manola, M. Bertagnolli, G. Demetri, 2009, European journal of cancer.

Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

C. Paweletz, V. Velculescu, J. Fletcher, 2018 .

Association of p300 and CBP with simian virus 40 large T antigen

D. Livingston, J. Decaprio, J. Morgan, 1996, Molecular and cellular biology.

570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor

J. Fletcher, G. Demetri, S. George, 2006 .

383 POSTER A Phase I Study of dasatinib, a Src and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors

G. Demetri, P. LoRusso, V. Brunton, 2006 .

MALT) Lymphoma Lie within or near the Previously Undescribed Gene MALT1 in Chromosome 18 1

D. Weisenburger, C. Reynolds, N. Harris, 1999 .

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

G. Demetri, K. Ganjoo, S. George, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

Su-Chun Cheng, J. Fletcher, G. Demetri, 2005 .